Heart failure & cardiomyopathies
Lower Left Ventricular Ejection Time in MYBPC3 Variant Carriers with Overt or Subclinical Hypertrophic Cardiomyopathy
Authors' conclusion
The data suggest that variants in MYBPC3 and MYH7 result in distinct biophysical consequences, which can be detected by measuring LVETI in patients. The findings may have implications for potential genotype-specific differences in response to therapies targeting sarcomere function.
Study context
- Population
- Patients carrying MYBPC3 or MYH7 pathogenic variants (hypertrophic cardiomyopathy), compared with healthy controlspatients carrying MYBPC3 or MYH7 pathogenic variants, 44 healthy controls · discovery cohort MYBPC3 40 · discovery cohort MYH7 31 · validation cohort MYBPC3 54 · validation cohort MYH7 41 · healthy controls 44
- Participants
- 166 patients
- Exposure
- LVET index (LVETI) between variant carriers and controls
- Controlsn = 44
- Outcome
- LVETI, LVH+ patients
Methodological detailsdiscovery cohort and validation cohort
- Discovery cohort and validation cohort
Main finding
As reported in the abstract
MYBPC3 vs MYH7: P < 0.001 · MYBPC3 vs controls: P < 0.001 · MYH7 vs controls: P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | MYBPC3 | MYH7 | Controls | P value | |
|---|---|---|---|---|---|
| LVETI, LVH- patientsMYBPC3 vs MYH7 · pooled | 380 ± 16 ms | 437 ± 39 ms | Not reported in the abstract | P < 0.001 | controls: not reported in the abstract |
| LVETI, LVH- patientsMYBPC3 vs controls · pooled | P < 0.001 |
MYBPC3 variant type
- Truncating MYBPC3 variants
- 87%
- Non-truncating MYBPC3 variants
- 13%
- LVETI did not differ between truncating and non-truncating groups and was significantly lower than control in both
Original publication
Lower Left Ventricular Ejection Time in MYBPC3 Variant Carriers with Overt or Subclinical Hypertrophic Cardiomyopathy. ESC Heart Fail. Published 4 July 2025. doi:10.
Summarised from the published abstract; every number is checked against it